247 related articles for article (PubMed ID: 36291667)
1. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
[No Abstract] [Full Text] [Related]
2. Identification of the HNSC88 Molecular Signature for Predicting Subtypes of Head and Neck Cancer.
Chuang YH; Lin CY; Lee JC; Lee CH; Liu CL; Huang SH; Lee JY; Lai WS; Yang JM
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685875
[TBL] [Abstract][Full Text] [Related]
3. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
Huang J; Liang B; Wang T
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
5. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
6. Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer.
Murphy RM; Tasoulas J; Porrello A; Carper MB; Tsai YH; Coffey AR; Kumar S; Zeng PY; Schrank TP; Midkiff BR; Cohen S; Salazar AH; Hayward MC; Hayes DN; Olshan A; Gupta GP; Nichols AC; Yarbrough WG; Pecot CV; Amelio AL
Cancer Res Commun; 2022 Sep; 2(9):987-1004. PubMed ID: 36148399
[TBL] [Abstract][Full Text] [Related]
7. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
Hu R; Lu M; She L
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of significant genes and immune cell infiltration in HPV-related head and neck squamous cell carcinoma.
Xu L; Jin Y; Qin X
Int Immunopharmacol; 2020 Oct; 87():106844. PubMed ID: 32738592
[TBL] [Abstract][Full Text] [Related]
10. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
[TBL] [Abstract][Full Text] [Related]
11. CYP4F12 is a potential biomarker and inhibits cell migration of head and neck squamous cell carcinoma via EMT pathway.
Jia W; Chen S; Wei R; Yang X; Zhang M; Qian Y; Liu H; Lei D
Sci Rep; 2023 Jul; 13(1):10956. PubMed ID: 37414830
[TBL] [Abstract][Full Text] [Related]
12. MYO5A overexpression promotes invasion and correlates with low lymphocyte infiltration in head and neck squamous carcinoma.
Xing J; Gu Y; Song Y; Liu Q; Chen Q; Han P; Shen Z; Li H; Zhang S; Bai Y; Ma J; Sui F
BMC Cancer; 2023 Dec; 23(1):1267. PubMed ID: 38129784
[TBL] [Abstract][Full Text] [Related]
13. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics analysis of the role of CXC ligands in the microenvironment of head and neck tumor.
Jing F; Wang J; Zhou L; Ning Y; Xu S; Zhu Y
Aging (Albany NY); 2021 Jul; 13(13):17789-17817. PubMed ID: 34247149
[TBL] [Abstract][Full Text] [Related]
15. Identification of genetic mechanisms underlying lipid metabolism-mediated tumor immunity in head and neck squamous cell carcinoma.
Liu S; Wang S; Wang Z
BMC Med Genomics; 2023 May; 16(1):110. PubMed ID: 37210507
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic analysis of BGN in head and neck squamous cell carcinoma.
Zhao L; Liang J; Zhong W; Han C; Liu D; Chen X
Gene; 2022 Jun; 827():146461. PubMed ID: 35358652
[TBL] [Abstract][Full Text] [Related]
18. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas - comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients.
Knebel M; Körner S; Kühn JP; Wemmert S; Brust L; Smola S; Wagner M; Bohle RM; Morris LGT; Pandey A; Schick B; Linxweiler M
Front Immunol; 2023; 14():1172768. PubMed ID: 37383237
[TBL] [Abstract][Full Text] [Related]
20. Biomarker Potential of
Ju Y; Zhu F; Fang B
Int J Med Sci; 2024; 21(5):921-936. PubMed ID: 38617010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
